pharma
dog
News
when
Latest
Archive
by source
All Sources
Sources Page
Jobs
department
Clinical
Regulatory
Medical Affairs
Commercial
R&D / Discovery
Biostatistics / Data
Manufacturing / CMC
Market Access
therapeutic area
Oncology
Immunology
Neuroscience
Cardiovascular
Metabolic
Rare Disease
Infectious Disease
location & type
Remote Only
US Only
California
Massachusetts
Internships
Phase 3 Roles
All Jobs →
Drugs
by stage
Marketed
Phase 3
Phase 2
Phase 1
Preclinical
browse
Most catalysts
Recently active
All drugs →
Companies
Patent cliff
Calendar
what
Trial readouts
PDUFA dates
Approvals
Earnings
when
Upcoming
Month grid
Recently passed
◐
Sign In
Subscribe
home
jobs
news
search
Summit Therapeutics Inc. ($SMMT) · news · pharmadog
← back to Summit Therapeutics Inc.
News mentioning $SMMT
54
stories
Aug 19, 26
Amylyx’s redemption story, Summit’s survival woes, Definium’s anxiety win, more
biospace
Aug 17, 26
Summit, Akeso's ivonescimab shows smaller benefit with longer follow-up in China
endpoints
Aug 17, 26
Summit, Akeso’s China approval celebration cut short as survival benefit degrades
biospace
Aug 17, 26
STAT+: Akeso and Summit’s lung cancer drug shows worsening tumor-progression benefit
stat
Jul 29, 26
Merck posts—then pulls—trial plan for PD-1xVEGF and TROP2 ADC combination
fiercebiotech
Jul 28, 26
As pharma descends on China for deals, BIOSECURE Act raises intellectual property risk
biospace
Jul 27, 26
Summit, Merck must navigate new regulatory terrain in China-first cancer landscape
biospace
Jul 24, 26
Summit has less than a year of cash runway left as PD-1/VEGF verdict nears
biospace
Jul 22, 26
Summit and Akeso sharpen case for ivonescimab with new Western data
biospace
Jul 22, 26
STAT+: Pharma tries to tamp down broad China restrictions
stat
Jul 22, 26
Summit counters PD-1/VEGF skeptics; Celldex drug fails skin disease study
biopharma dive
Jul 22, 26
Summit reports two-year survival data for Western patients, though context lacking
endpoints
Jul 15, 26
J&J dips despite upbeat outlook; AstraZeneca, Spero cut China deals
biopharma dive
Jul 14, 26
Erasca's $550M offering; Summit sells an antibiotic
endpoints
Jun 29, 26
10 clinical trials to watch in the second half of 2026
biopharma dive
Jun 11, 26
Summit pulls $500M share sale a day after announcing it
biopharma dive
Jun 11, 26
Summit withdraws $500M offering, citing 'market conditions'
endpoints
Jun 5, 26
Pharma is betting big on PD-1/VEGF bispecifics. But are companies chasing the wrong target?
biopharma dive
May 31, 26
#ASCO26: Summit, Akeso drug reduces death by 34% in China lung cancer study
endpoints
May 31, 26
STAT+: Akeso and Summit’s ivonescimab extends survival in squamous cell lung cancer
stat
May 31, 26
Akeso, Summit drug extends survival in closely watched lung cancer trial
biopharma dive
May 1, 26
Summit’s ‘self-inflicted’ stumble; Esperion’s take-private deal
biopharma dive
May 1, 26
Summit slips on ivonescimab's apparent interim miss in sign of investor frustration
endpoints
Apr 30, 26
STAT+: What does Akeso’s primo plenary spot say about its survival data?
stat
← prev
page 2 of 2
next →
